Neurocognitive outcomes in pediatric hematological cancer survivors post‐HSCT: A systematic review
Нейрокогнитивные исходы у детей, перенесших гематологический рак, после трансплантации гемопоэтических стволовых клеток: систематический обзор
2023-11-15
SCID: 54.1/6p6h2pxc
Discuss with AI
graft-versus-host diseasehematopoietic stem cell transplantationneurocognitive outcomespediatric hematological cancer survivorsprocessing speed
Figures from the paper
Abstract (AI)
BACKGROUND: Pediatric hematological cancer survivors who undergo hematopoietic stem cell transplantation (HSCT) may experience long-term neurocognitive impairments. This systematic review aims to assess the neurocognitive outcomes in pediatric hematological cancer survivors at least 5 years post-HSCT. METHODOLOGY: A comprehensive search was conducted in multiple databases, including PubMed, ScienceDirect, Cochrane Library, and ClinicalTrials.gov, until October 2022. Relevant studies assessing the neurocognitive affect after 5 years of HSCT were identified and included in the review. The quality of included studies was assessed using the ROBINS-I tool to evaluate the risk of bias. RESULTS: A total of five studies met the inclusion criteria and were included in the review. The studies consistently demonstrated adverse effects of HSCT on neurocognitive outcomes in pediatric hematological cancer survivors after 5 years of the treatment. The most prominent impact was observed on global cognitive outcomes, including intelligence, attention, memory, and executive functioning. Specific cognitive domains, such as processing speed and academic achievement, were also significantly affected. Several studies reported a relationship between HSCT-related factors (e.g., age at transplantation, radiation therapy, graft-versus-host disease) and neurocognitive impairments. CONCLUSION: This systematic review provides evidence of the adverse impact of HSCT on neurocognitive outcomes in pediatric hematological cancer survivors at least 5 years post-transplantation. The findings highlight the importance of long-term monitoring and intervention strategies to mitigate these neurocognitive sequelae. Future research should focus on identifying risk factors and developing targeted interventions to optimize the neurocognitive functioning of this vulnerable population. Healthcare professionals involved in the care of pediatric hematological cancer survivors should be aware of these potential long-term neurocognitive effects and incorporate appropriate assessments and interventions into survivorship care plans.
Key Findings
1
A systematic review of five studies found consistently adverse neurocognitive outcomes in pediatric hematological cancer survivors at least five years after HSCT.
2
Age at transplantation, radiation therapy, and graft-versus-host disease were reported as factors associated with neurocognitive impairment.
3
HSCT was associated with impairments in global cognition, including intelligence, attention, memory, and executive functioning.
4
Processing speed and academic achievement were also significantly affected after long-term follow-up.
5
The findings support long-term neurocognitive monitoring and targeted interventions, while further research should identify risk factors and optimize survivor functioning.
Research Object
pediatric hematological cancer survivors at least 5 years after hematopoietic stem cell transplantation (HSCT)
Research Subject
long-term neurocognitive outcomes and impairments, including intelligence, attention, memory, executive functioning, processing speed, and academic achievement, and their associations with HSCT-related factors
Publication Details
Publication Date
2023-11-15
Journal
Publisher
ISSN
Cited by
6
Access Type
Author Information
Download PDF
Subscribe to digest